ArticleClinical Medicine Insights. Oncology2022

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.

Minal Barve et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.